Mycobacterium cell wall: An alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer

Journal of Urology

Volumn 156, Issue 3, 1996, Pages 1189-1193

  Chin, Joseph L ^a   Kadhim, Salam A ^b   Batislam, Ertan ^b   Karlik, Stephen J ^b   Garcia, Bertha M ^b   Nickel, J Curtis ^b   Morales, Alvaro ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NONE

Author keywords

BCG vaccine; bladder neoplasms; Mycobacterium phlei

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL MEMBRANE; BCG VACCINATION; BLADDER CANCER; CANCER INHIBITION; CATHA EDULIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; MOUSE; MYCOBACTERIUM; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0029737531     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65748-3     Document Type: Article

References (17)

1. Morales, A.: Treatment of carcinoma in situ of the bladder with BCG. A Phase II trial. Cancer Immunol. Immunother., 9: 69, 1980.
2. Morales, A.: Long term results of BCG therapy for bladder cancer. J. Urol., 132: 457, 1984.
3. Lamm, D. L., van der Meijden, A. D. and Morales, A.: Incidence and treatment of complications of bacillus Calmette Guerin intravesical therapy in superficial bladder cancer. J. Urol., 147: 596, 1992.
4. Chin, J. L., Kadhim, S. A., Garcia, B. M., Kim, Y. S. and Karlik, S. J.: Magnetic resonance imaging for detection and treatment monitoring of orthotopic murine bladder tumor implants. J. Urol., 145: 1297, 1991.
5. Kadhim, S. A., Chin, J. L., Garcia, B. M., Lala, P. K., Norley, C. J., McLean, B. A. and Karlik, S. J.: BRM immunotherapy of orthotopically implanted murine bladder tumors: treatment response monitoring by MRI. Can. J. Infect. Dis., suppl. B, 3: 143B, 1992.
6. Soloway, M. S.: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res., 37: 2918, 1979.
7. Weinshenker, B. G., Baas, R. N. and Karlik, S. J.: An open trial of OKT3 in patients with multiple sclerosis. Neurology, 41: 1047, 1991.
8. Fradet, Y., Tardiff, M., Bourget, L., Robert, J. and the Laval University Urology Group: Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res., 50: 432, 1990.
9. deBoer, E. C., Steerenberg, P. A., van der Meijden, A. P., van Klingeren, B., de Jong, W. H., Elgersma, A., Debruyne, F. M. J. and Ruitenberg, E. J.: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J. Urol., 148: 1577, 1992.
10. Bohle, A.: Prospects for improving the efficacy of BCG. Eur. Urol., suppl., 21: 22, 1992.
11. Chin, J. L., Kadhim, S. A., Batislam, E., Skamene, E., Karlik, S. J. and Garcia, B.: Intravesical bacillus Calmette Guerin (BCG) in the murine bladder tumor: comparison of efficacy in BCG-sensitive and BCG-resistant congenic strains of mice. J. Urol., 149: 224A, 1993.
12. Fifis, T., Costopoulos, C. M., Radford, A. J., Bacic, A. and Wood, P. R.: Purification and characterization of major antigens from a Mycobacterium bovis culture filtrate. J. Infect. Immunol., 59: 800, 1991.
13. Beschin, A., Brijs, L., de Baetselier, P. and Cocito, C.: Mycobacterial proliferation in macrophages is prevented by incubation with lymphocytes activated in vitro with a mycobacterial antigen complex. Eur. J. Immunol., 21: 793, 1991.
14. Nickel, J. C., Morales, A. and Costerton, J. W.: On the elusive nature of BCG-host interactions: towards a better vaccine. J. Urol., 141: 291A, 1989.
15. Bioniche, Inc.: Unpublished data, research report, London, Ontario, Canada, 1992.
16. Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. and Catalona, W. J.: T cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol., 150: 1018, 1993.
17. Cornel, E. B., van Moorselaar, R. J. A., van Stratum, P., Debruyne, F. M. and Schalken, J. A.: Antitumor effects of bacillus Calmette-Guerin in a syngeneic rat bladder tumor model system RBT323. J. Urol., 149: 179, 1993.